Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-001 dose-escalation study in previously treated wet AMD
ChiCTR2300074365Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AL001 in exudative macular degeneration (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Safety. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
AL001
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2300074365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074365.